TrialCardiovascular diabetology2017

Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.

Alessandra Dei Cas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.